SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel cancer therapeutics. The company's primary focus is on immunotherapy and targeted small molecule treatments for hematologic malignancies and solid tumors. Its lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy targeting Wilms tumor 1 antigen, which is being evaluated in combination with Merck's PD-1 inhibitor pembrolizumab across multiple cancer indications. The company's second major candidate is SLS009 (tambiciclib), a selective CDK9 inhibitor being developed as a small molecule therapeutic approach.

The company operates through strategic collaborations that extend its pipeline and development capabilities. A significant partnership with Merck involves a Phase 1/2 clinical trial combining GPS with pembrolizumab in patients with up to five cancer indications. Additionally, SELLAS maintains a collaboration with GenFleet Therapeutics (Shanghai), Inc. for development and commercialization of GFH009, indicating expansion into Asian markets.

As a clinical-stage biopharmaceutical company, SELLAS operates with a lean organizational structure of 15 full-time employees and is headquartered in New York. The company is listed on the Nasdaq exchange and incorporated in Delaware, reflecting its structure as a publicly traded U.S. biopharmaceutical developer with a market capitalization of approximately $0.8 billion.